Association of MSH6 mutation with glioma susceptibility, drug resistance and progression

被引:26
作者
Xie, Chaoran [1 ,2 ]
Sheng, Hansong [2 ]
Zhang, Nu [2 ]
Li, Shiting [1 ]
Wei, Xiangyu [1 ]
Zheng, Xuesheng [1 ]
机构
[1] Shanghai Jiao Tong Univ, Dept Neurosurg, Xinhua Hosp, Sch Med, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China
[2] Wenzhou Med Univ, Dept Neurosurg, Affiliated Hosp 2, Wenzhou 325027, Zhejiang, Peoples R China
关键词
mutS homolog 6; mutation; glioma; drug resistance; temozolomide;
D O I
10.3892/mco.2016.907
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
MutS homolog 6 (MSH6) is one of the mismatch repair proteins and is encoded by the MSH6 gene, which is located on chromosome 2 and is 23,806 bp in length, including 10 exons and 83 untranslated regions. The MSH6 protein consists of 1,358 amino acid residues and forms a heterodimer with another mismatch repair protein, MSH2. The MSH2-MSH6 heterodimeric complex is able to recognize base-base substitution and single-base insertion/deletion mismatches. Germline mutations of MSH6 lead to high susceptibility to glioma, as well as a number of benign or malignant tumors in other organs. However, somatic MSH6 mutations are not associated with susceptibility to glioma. Somatic MSH6 mutations usually follow temozolomide treatment and result in resistance to temozolomide. Subsequently, MSH6 mutations cause a hypermutation in the glioma cell genome, which may accelerate tumor progression.
引用
收藏
页码:236 / 240
页数:5
相关论文
共 31 条
[1]   Risks of Lynch Syndrome Cancers for MSH6 Mutation Carriers [J].
Baglietto, Laura ;
Lindor, Noralane M. ;
Dowty, James G. ;
White, Darren M. ;
Wagner, Anja ;
Garcia, Encarna B. Gomez ;
Vriends, Annette H. J. T. ;
Cartwright, Nicola R. ;
Barnetson, Rebecca A. ;
Farrington, Susan M. ;
Tenesa, Albert ;
Hampel, Heather ;
Buchanan, Daniel ;
Arnold, Sven ;
Young, Joanne ;
Walsh, Michael D. ;
Jass, Jeremy ;
Macrae, Finlay ;
Antill, Yoland ;
Winship, Ingrid M. ;
Giles, Graham G. ;
Goldblatt, Jack ;
Parry, Susan ;
Suthers, Graeme ;
Leggett, Barbara ;
Butz, Malinda ;
Aronson, Melyssa ;
Poynter, Jenny N. ;
Baron, John A. ;
Le Marchand, Loic ;
Haile, Robert ;
Gallinger, Steve ;
Hopper, John L. ;
Potter, John ;
de la Chapelle, Albert ;
Vasen, Hans F. ;
Dunlop, Malcolm G. ;
Thibodeau, Stephen N. ;
Jenkins, Mark A. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (03) :193-201
[2]   Diversity of the clinical presentation of the MMR gene biallelic mutations [J].
Bougeard, Gaelle ;
Olivier-Faivre, Laurence ;
Baert-Desurmont, Stephanie ;
Tinat, Julie ;
Martin, Cosette ;
Bouvignies, Emilie ;
Vasseur, Stephanie ;
Huet, Frederic ;
Couillault, Gerard ;
Vabres, Pierre ;
Le Pessot, Florence ;
Chapusot, Caroline ;
Malka, David ;
Bressac-de Paillerets, Brigitte ;
Tosi, Mario ;
Frebourg, Thierry .
FAMILIAL CANCER, 2014, 13 (01) :131-135
[3]   Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment [J].
Cahill, Daniel P. ;
Levine, Kymberly K. ;
Betensky, Rebecca A. ;
Codd, Patrick J. ;
Romany, Candice A. ;
Reavie, Linsey B. ;
Batchelor, Tracy T. ;
Futreal, P. Andrew ;
Stratton, Michael R. ;
Curry, William T. ;
Iafrate, A. John ;
Louis, David N. .
CLINICAL CANCER RESEARCH, 2007, 13 (07) :2038-2045
[4]  
Cahill Daniel P, 2008, Clin Neurosurg, V55, P165
[5]   Comprehensive genomic characterization defines human glioblastoma genes and core pathways [J].
Chin, L. ;
Meyerson, M. ;
Aldape, K. ;
Bigner, D. ;
Mikkelsen, T. ;
VandenBerg, S. ;
Kahn, A. ;
Penny, R. ;
Ferguson, M. L. ;
Gerhard, D. S. ;
Getz, G. ;
Brennan, C. ;
Taylor, B. S. ;
Winckler, W. ;
Park, P. ;
Ladanyi, M. ;
Hoadley, K. A. ;
Verhaak, R. G. W. ;
Hayes, D. N. ;
Spellman, Paul T. ;
Absher, D. ;
Weir, B. A. ;
Ding, L. ;
Wheeler, D. ;
Lawrence, M. S. ;
Cibulskis, K. ;
Mardis, E. ;
Zhang, Jinghui ;
Wilson, R. K. ;
Donehower, L. ;
Wheeler, D. A. ;
Purdom, E. ;
Wallis, J. ;
Laird, P. W. ;
Herman, J. G. ;
Schuebel, K. E. ;
Weisenberger, D. J. ;
Baylin, S. B. ;
Schultz, N. ;
Yao, Jun ;
Wiedemeyer, R. ;
Weinstein, J. ;
Sander, C. ;
Gibbs, R. A. ;
Gray, J. ;
Kucherlapati, R. ;
Lander, E. S. ;
Myers, R. M. ;
Perou, C. M. ;
McLendon, Roger .
NATURE, 2008, 455 (7216) :1061-1068
[6]   Mutation in the mismatch repair gene Msh6 causes cancer susceptibility [J].
Edelmann, W ;
Yang, K ;
Umar, A ;
Heyer, J ;
Lau, K ;
Fan, KH ;
Liedtke, W ;
Cohen, PE ;
Kane, MF ;
Lipford, JR ;
Yu, NJ ;
Crouse, GF ;
Pollard, JW ;
Kunkel, T ;
Lipkin, M ;
Kolodner, R ;
Kucherlapati, R .
CELL, 1997, 91 (04) :467-477
[7]   Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas [J].
Felsberg, Joerg ;
Thon, Niklas ;
Eigenbrod, Sabina ;
Hentschel, Bettina ;
Sabel, Michael C. ;
Westphal, Manfred ;
Schackert, Gabriele ;
Kreth, Friedrich Wilhelm ;
Pietsch, Torsten ;
Loeffler, Markus ;
Weller, Michael ;
Reifenberger, Guido ;
Tonn, Joerg C. .
INTERNATIONAL JOURNAL OF CANCER, 2011, 129 (03) :659-670
[8]   Regulation of the human MSH6 gene by the Sp1 transcription factor and alteration of promoter activity and expression by polymorphisms [J].
Gazzoli, I ;
Kolodner, RD .
MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (22) :7992-8007
[9]   An Ashkenazi founder mutation in the MSH6 gene leading to HNPCC [J].
Goldberg, Yael ;
Porat, Rinnat M. ;
Kedar, Inbal ;
Shochat, Chen ;
Galinsky, Daliah ;
Hamburger, Tamar ;
Hubert, Ayala ;
Strul, Hana ;
Kariiv, Revital ;
Ben-Avi, Liat ;
Savion, Moran ;
Pikarsky, Eli ;
Abeliovich, Dvorah ;
Bercovich, Dani ;
Lerer, Israela ;
Peretz, Tamar .
FAMILIAL CANCER, 2010, 9 (02) :141-150
[10]   A homozygous mutation in MSH6 causes Turcot syndrome [J].
Hegde, MR ;
Chong, B ;
Blazo, ME ;
Chin, LHE ;
Ward, PA ;
Chintagumpala, MM ;
Kim, JY ;
Plon, SE ;
Richards, CS .
CLINICAL CANCER RESEARCH, 2005, 11 (13) :4689-4693